Shivaani Kummar

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. pmc Advances in using PARP inhibitors to treat cancer
    Shivaani Kummar
    Division of Cancer Treatment and Diagnosis, 31 Center Drive, National Cancer Institute, Bethesda, MD 20892, USA
    BMC Med 10:25. 2012
  2. doi request reprint Molecular targets in cancer therapy
    Shivaani Kummar
    Division of Cancer Treatment and Diagnosis and Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
    Expert Rev Anticancer Ther 13:267-9. 2013
  3. pmc Cediranib for metastatic alveolar soft part sarcoma
    Shivaani Kummar
    National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Clin Oncol 31:2296-302. 2013
  4. pmc Phase I trial of vandetanib and bevacizumab evaluating the VEGF and EGF signal transduction pathways in adults with solid tumours and lymphomas
    Shivaani Kummar
    Center for Cancer Research, National Cancer Institute, 10 Center Drive, Bethesda, MD 20892, USA
    Eur J Cancer 47:997-1005. 2011
  5. pmc A phase I trial of UCN-01 and prednisone in patients with refractory solid tumors and lymphomas
    Shivaani Kummar
    Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
    Cancer Chemother Pharmacol 65:383-9. 2010
  6. pmc Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies
    Shivaani Kummar
    Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
    Eur J Cancer 46:340-7. 2010
  7. doi request reprint Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia
    Cody J Peer
    Clinical Pharmacology Program, Pharmacology and Experimental Therapeutics Section, Molecular Pharmacology Section, Biostatistics and Data Management Branch, Medical Oncology Branch, and HIV AIDS Malignancy Branch, National Cancer Institute, Bethesda, MD 20892, USA
    Clin Cancer Res 18:2099-107. 2012
  8. doi request reprint Pharmacogenetically driven patient selection for a first-in-human phase I trial of batracylin in patients with advanced solid tumors and lymphomas
    Shivaani Kummar
    Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
    Cancer Chemother Pharmacol 72:917-23. 2013
  9. pmc Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies
    Shivaani Kummar
    Center for Cancer Research and the Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Bethesda, MD 20892, USA
    J Clin Oncol 27:2705-11. 2009
  10. doi request reprint A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors
    Arun Rajan
    Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Clin Cancer Res 18:2344-51. 2012

Detail Information

Publications52

  1. pmc Advances in using PARP inhibitors to treat cancer
    Shivaani Kummar
    Division of Cancer Treatment and Diagnosis, 31 Center Drive, National Cancer Institute, Bethesda, MD 20892, USA
    BMC Med 10:25. 2012
    ....
  2. doi request reprint Molecular targets in cancer therapy
    Shivaani Kummar
    Division of Cancer Treatment and Diagnosis and Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
    Expert Rev Anticancer Ther 13:267-9. 2013
    ....
  3. pmc Cediranib for metastatic alveolar soft part sarcoma
    Shivaani Kummar
    National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Clin Oncol 31:2296-302. 2013
    ..Cediranib is a potent, oral small-molecule inhibitor of all three vascular endothelial growth factor receptors (VEGFRs)...
  4. pmc Phase I trial of vandetanib and bevacizumab evaluating the VEGF and EGF signal transduction pathways in adults with solid tumours and lymphomas
    Shivaani Kummar
    Center for Cancer Research, National Cancer Institute, 10 Center Drive, Bethesda, MD 20892, USA
    Eur J Cancer 47:997-1005. 2011
    ..We designed a phase I study to evaluate the combination of vandetanib, an investigational agent with activity against EGF receptor and VEGF receptor 2, and bevacizumab, a monoclonal antibody against VEGF...
  5. pmc A phase I trial of UCN-01 and prednisone in patients with refractory solid tumors and lymphomas
    Shivaani Kummar
    Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
    Cancer Chemother Pharmacol 65:383-9. 2010
    ..We designed a phase I study to determine the maximum tolerated dose (MTD) of UCN-01 with prednisone in patients with advanced malignancies...
  6. pmc Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies
    Shivaani Kummar
    Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
    Eur J Cancer 46:340-7. 2010
    ....
  7. doi request reprint Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia
    Cody J Peer
    Clinical Pharmacology Program, Pharmacology and Experimental Therapeutics Section, Molecular Pharmacology Section, Biostatistics and Data Management Branch, Medical Oncology Branch, and HIV AIDS Malignancy Branch, National Cancer Institute, Bethesda, MD 20892, USA
    Clin Cancer Res 18:2099-107. 2012
    ..We hypothesized that sorafenib inhibits UGT1A1 and individuals carrying UGT1A1*28 and/or UGT1A9 variants experience greater sorafenib exposure and greater increase in sorafenib-induced plasma bilirubin concentration...
  8. doi request reprint Pharmacogenetically driven patient selection for a first-in-human phase I trial of batracylin in patients with advanced solid tumors and lymphomas
    Shivaani Kummar
    Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
    Cancer Chemother Pharmacol 72:917-23. 2013
    ..The objectives were to determine the safety, maximum tolerated dose (MTD), and pharmacokinetics of batracylin and its metabolites...
  9. pmc Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies
    Shivaani Kummar
    Center for Cancer Research and the Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Bethesda, MD 20892, USA
    J Clin Oncol 27:2705-11. 2009
    ..It was a first-in-human study of the poly (ADP-ribose) polymerase (PARP) inhibitor ABT-888 in patients with advanced malignancies...
  10. doi request reprint A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors
    Arun Rajan
    Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Clin Cancer Res 18:2344-51. 2012
    ..To determine the safety and tolerability of olaparib with cisplatin and gemcitabine, establish the maximum tolerated dose (MTD), and evaluate the pharmacodynamic and pharmacokinetic profile of the combination...
  11. ncbi request reprint Pilot trial of EZN-2968, an antisense oligonucleotide inhibitor of hypoxia-inducible factor-1 alpha (HIF-1α), in patients with refractory solid tumors
    Woondong Jeong
    Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, 20892, USA
    Cancer Chemother Pharmacol 73:343-8. 2014
    ..We conducted a trial of EZN-2968 in patients with refractory solid tumors to evaluate antitumor response and to measure modulation of HIF-1α mRNA and protein levels as well as HIF-1 target genes...
  12. pmc Poly(ADP-ribose) polymerase inhibition enhances p53-dependent and -independent DNA damage responses induced by DNA damaging agent
    Diana Nguyen
    Division of Cancer Treatment and Diagnosis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Cell Cycle 10:4074-82. 2011
    ..Abrogating the cell-cycle arrest induced by PARP inhibition plus chemotherapeutics may be a strategy in the treatment of BRCA-proficient cancer...
  13. ncbi request reprint Immunohistochemical detection of poly(ADP-ribose) polymerase inhibition by ABT-888 in patients with refractory solid tumors and lymphomas
    Sherry X Yang
    Division of Cancer Treatment and Diagnosis, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA
    Cancer Biol Ther 8:2004-9. 2009
    ..We aimed to determine whether the PARP inhibitor ABT-888 hits its therapeutic target in tumors by immunohistochemistry during a Phase 0 trial conducted at the National Cancer Institute...
  14. pmc A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomas
    Arun Rajan
    Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Clin Cancer Res 17:6831-9. 2011
    ..To determine the maximum tolerated dose (MTD), toxicities, and pharmacokinetic/pharmacodynamic profile of the Hsp90 inhibitor PF-04929113 (SNX-5422) in patients with advanced solid tumors and lymphomas...
  15. pmc Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas
    Shivaani Kummar
    Center for Cancer Research and Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, USA
    Cancer Res 71:5626-34. 2011
    ..Results of this trial reveal that PARP inhibition can modulate the capacity to repair topoisomerase I-mediated DNA damage in the clinic...
  16. pmc Population pharmacokinetic analysis of sorafenib in patients with solid tumours
    Lokesh Jain
    Clinical Pharmacology Program Medical Oncology Branch, National Cancer Institute, NIH, Bethesda, MD 20892, USA
    Br J Clin Pharmacol 72:294-305. 2011
    ..The pharmacokinetics (PK) of sorafenib are highly variable between subjects. Sorafenib exposure increases less than dose proportionally (likely due to limited solubility). Sorafenib undergoes enterohepatic recycling (EHC)...
  17. doi request reprint Phase I study of the synthetic triterpenoid, 2-cyano-3, 12-dioxoolean-1, 9-dien-28-oic acid (CDDO), in advanced solid tumors
    Giovanna Speranza
    Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA
    Cancer Chemother Pharmacol 69:431-8. 2012
    ....
  18. doi request reprint A multi-histology trial of fostamatinib in patients with advanced colorectal, non-small cell lung, head and neck, thyroid, and renal cell carcinomas, and pheochromocytomas
    Sook Ryun Park
    Division of Cancer Treatment and Diagnosis, National Cancer Institute, 31 Center Drive, 3A44, Bethesda, MD 20892, USA
    Cancer Chemother Pharmacol 71:981-90. 2013
    ....
  19. doi request reprint Histone deacetylase inhibitors in cancer therapy
    Min Jung Lee
    Medical Oncology Branch, Center for Cancer Research, NCI, NIH, Bethesda, Maryland 20892, USA
    Curr Opin Oncol 20:639-49. 2008
    ..The purpose of this review is to provide an overview of recent advances in the development of histone deacetylase inhibitors (HDACi) for the treatment of cancer...
  20. doi request reprint The statistics of phase 0 trials
    Larry V Rubinstein
    Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD 20892, USA
    Stat Med 29:1072-6. 2010
    ..The phase 0 trial promises to become an increasingly important tool for facilitating and speeding the development of new therapeutic agents, particularly in oncology...
  21. ncbi request reprint Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies
    Shivaani Kummar
    Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA
    Clin Cancer Res 13:5411-7. 2007
    ..The aims of this phase I trial were to determine the dose-limiting toxicities and maximum tolerated dose of oral MS-275 in humans administered with food on a once weekly schedule and to study the pharmacokinetics of oral MS-275...
  22. pmc Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenib
    Ronan J Kelly
    Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892 1457, USA
    Clin Cancer Res 17:1190-9. 2011
    ..Sorafenib, a multikinase inhibitor targeting Raf and VEGFR, has shown activity in unselected patients with non-small-cell lung cancer (NSCLC). At present there are no validated biomarkers indicative of sorafenib activity...
  23. ncbi request reprint Safety and feasibility of targeted agent combinations in solid tumours
    Sook Ryun Park
    Division of Cancer Treatment and Diagnosis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Building 31, Room 3A44, 31 Center Drive, Bethesda, MD 20892, USA
    Nat Rev Clin Oncol 10:154-68. 2013
    ..Toxicities caused by MTA combinations highlight the need to introduce new preclinical testing paradigms early in the drug development process for the assessment of chronic toxicities resulting from such combinations...
  24. pmc Monitoring drug-induced gammaH2AX as a pharmacodynamic biomarker in individual circulating tumor cells
    Lihua H Wang
    Laboratory of Human Toxicology and Pharmacology, Science Applications International Corporation, Frederick, MD, USA
    Clin Cancer Res 16:1073-84. 2010
    ..Here, we describe an assay that directly examines changes in levels of the nuclear DNA damage marker gammaH2AX in individual CTCs of patients treated with chemotherapeutic agents...
  25. pmc A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas
    Shivaani Kummar
    National Cancer Institute, Bethesda, MD, USA
    Clin Cancer Res 18:1726-34. 2012
    ..We conducted a phase I trial of the PARP inhibitor veliparib and metronomic cyclophosphamide in patients with refractory solid tumors and lymphoid malignancies...
  26. doi request reprint Weekly EZN-2208 (PEGylated SN-38) in combination with bevacizumab in patients with refractory solid tumors
    Woondong Jeong
    Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, 20892, USA
    Invest New Drugs 32:340-6. 2014
    ..We hypothesized that co-administration of pegylated SN-38 (EZN-2208) may offset the induction of HIF-1α following bevacizumab treatment, resulting in synergistic antitumor effects...
  27. pmc Pharmacodynamic assessment of histone deacetylase inhibitors: infrared vibrational spectroscopic imaging of protein acetylation
    Tsoching Chen
    Laboratory of Chemical Physics, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Anal Chem 80:6390-6. 2008
    ..The data demonstrate a new approach to a sensitive assessment of global molecular modifications that is independent of antibodies, requires minimal cell processing, and is easily adapted to high-throughput screening...
  28. pmc Designing phase 0 cancer clinical trials
    Anthony J Murgo
    Division of Cancer Treatment and Diagnosis and Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892 2440, USA
    Clin Cancer Res 14:3675-82. 2008
    ....
  29. pmc Multihistology, target-driven pilot trial of oral topotecan as an inhibitor of hypoxia-inducible factor-1α in advanced solid tumors
    Shivaani Kummar
    Center for Cancer Research and Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD 21702, USA
    Clin Cancer Res 17:5123-31. 2011
    ..We designed a pilot trial to measure HIF-1α inhibition in tumor biopsies from patients with advanced solid tumors overexpressing HIF-1α, after treatment with oral topotecan...
  30. pmc First-in-human phase 0 trial of oral 5-iodo-2-pyrimidinone-2'-deoxyribose in patients with advanced malignancies
    Shivaani Kummar
    Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD 20892, USA
    Clin Cancer Res 19:1852-7. 2013
    ..i.v. infusion before embarking on large-scale clinical trials. Plasma concentrations of IPdR, IdUrd, and other metabolites were measured after a single oral dose of IPdR...
  31. doi request reprint Next generation oncology drug development: opportunities and challenges
    Martin E Gutierrez
    National Cancer Institute, NIH, Bethesda, MD 20892, USA
    Nat Rev Clin Oncol 6:259-65. 2009
    ..We present a review of the opportunities and challenges facing drug development in oncology through the phases of clinical development starting with first-in-human trials...
  32. pmc Determination of 17-dimethylaminoethylamino-17-demethoxygeldanamycin in human plasma by liquid chromatography with mass-spectrometric detection
    Xiaohong Chen
    Clinical Pharmacology Program, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
    J Chromatogr B Analyt Technol Biomed Life Sci 858:302-6. 2007
    ..5% and 1.4% to 3.3%, respectively. The assay modifications significantly improve upon our original, validated method. The developed method was subsequently applied to study the pharmacokinetics of 17-DMAG in a group of 23 patients...
  33. ncbi request reprint Compressing drug development timelines in oncology using phase '0' trials
    Shivaani Kummar
    Center for Cancer Research, SAIC Frederick, Inc, NCI Frederick, Frederick, Maryland, USA
    Nat Rev Cancer 7:131-9. 2007
    ..We expect that such trials will become a routine part of early-phase oncological drug development in the future...
  34. doi request reprint Phase 0 clinical trials: conceptions and misconceptions
    Shivaani Kummar
    Center for Cancer Research, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland 20892, USA
    Cancer J 14:133-7. 2008
    ..We review here the fundamental requirements of clinical studies conducted under an exploratory IND and address some common misconceptions regarding oncologic phase 0 trials...
  35. pmc Phase 0 clinical trials: recommendations from the Task Force on Methodology for the Development of Innovative Cancer Therapies
    Shivaani Kummar
    Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USA
    Eur J Cancer 45:741-6. 2009
    ..Construction of a 'decision chart' was highly recommended to assist investigators and sponsors in determining whether an agent is suitable for evaluation in a Phase 0 trial...
  36. pmc Drug development in oncology: classical cytotoxics and molecularly targeted agents
    Shivaani Kummar
    Medical Oncology Branch, Center for Cancer Research and Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD 20892, USA
    Br J Clin Pharmacol 62:15-26. 2006
    ..Thus, there is an increasing interest in making the best possible use of biomarkers and pharmacogenomics in early phases of drug development...
  37. ncbi request reprint Adenocarcinoma of the small bowel: changes in the landscape?
    Giovanna Speranza
    Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland 20892, USA
    Curr Opin Oncol 22:387-93. 2010
    ..In recent years, improved diagnostic imaging and an increase in reported experience with use of chemotherapy may alter the way we manage SBA. This review will summarize recent advances in characterization, imaging, and treatment of SBA...
  38. ncbi request reprint Validation of a hypoxia-inducible factor-1 alpha specimen collection procedure and quantitative enzyme-linked immunosorbent assay in solid tumor tissues
    Sook Ryun Park
    Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD 20892, USA
    Anal Biochem 459:1-11. 2014
    ..5μg of total protein extract, and this method is currently being applied to analyze tumor biopsy specimens in early-phase clinical trials. ..
  39. pmc Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib
    Lokesh Jain
    Clinical Pharmacology Program, Center for Cancer Research, National Cancer Institute, 9000 Rockville Pike, Bethesda, MD 20892, USA
    J Exp Clin Cancer Res 29:95. 2010
    ..We hypothesized that these toxicities would correspond to favorable outcome in these drugs, that HT and HFSR would coincide, and that VEGFR2 genotypic variation would be related to toxicity and clinical outcomes...
  40. pmc Role of insulin-like growth factor-1R system in colorectal carcinogenesis
    Erin A Donovan
    Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, 9000 Rockville Pike, Building 10 12N226, Bethesda, MD 20892, United States
    Crit Rev Oncol Hematol 66:91-8. 2008
    ..Due to the complexity of this system, we have focused the review on the role of the IGF-1 receptor and its ligands in colorectal carcinogenesis and the strategies to block this pathway as a potential anti-cancer therapy...
  41. ncbi request reprint Phase I trial of fenretinide lym-x-sorb oral powder in adults with solid tumors and lymphomas
    Shivaani Kummar
    National Cancer Institute, Building 31, Room 3A44, 31 Center Drive, National Institutes of Health, Bethesda, MD 20892, USA
    Anticancer Res 31:961-6. 2011
    ..A novel lipid matrix, Lym-X-Sorb (LXS), was evaluated to improve fenretinide bioavailability and attain higher plasma concentrations...
  42. doi request reprint Targeting mitogen-activated protein kinase kinase (MEK) in solid tumors
    Austin Duffy
    Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, 9000 Rockville Pike, 10 13N240G, Bethesda, MD 20892, USA
    Target Oncol 4:267-73. 2009
    ..This article reviews the current status of MEK inhibitors with regard to their clinical development...
  43. doi request reprint Role of Phase 0 trials in drug development
    James H Doroshow
    Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Bethesda, MD 20892, USA
    Future Med Chem 1:1375-80. 2009
    ....
  44. ncbi request reprint Targeting VEGF in cancer therapy
    Erin A Donovan
    Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Curr Probl Cancer 30:7-32. 2006
  45. pmc Phase 0 trials: expediting the development of chemoprevention agents
    Shivaani Kummar
    Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Bethesda, MD 20892, USA
    Cancer Prev Res (Phila) 4:288-92. 2011
    ....
  46. ncbi request reprint False elevations in prostate-specific antigen levels affecting patient management
    Shivaani Kummar
    VA Connecticut Cancer Center, Yale Cancer Center, West Haven, CT 06516, USA
    Clin Adv Hematol Oncol 2:599-601; discussion 602. 2004
  47. doi request reprint Antiangiogenic approaches for the treatment of advanced synovial sarcomas
    Khanh Do
    Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA
    Curr Opin Oncol 24:425-30. 2012
    ..In light of the vascular nature of sarcomas, current molecularly targeted therapies aim at an antiangiogenic approach to management of this disease...
  48. ncbi request reprint Determination of the heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin in plasma by liquid chromatography-electrospray mass spectrometry
    Kyunghwa Hwang
    Clinical Pharmacology Research Core, Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
    J Chromatogr B Analyt Technol Biomed Life Sci 830:35-40. 2006
    ..The values for precision and accuracy were always <8% and <10% relative error, respectively. The method was successfully applied to examine the pharmacokinetics of 17-DMAG in a cancer patient...
  49. ncbi request reprint Non-small-cell lung cancer vaccine therapy: a concise review
    Deirdre O'Mahony
    Medical Oncology Clinical Research Unit, Center for Cancer Research, 10 Center Dr, Building 10, Room 12N226, Bethesda, MD 20892 1906, USA
    J Clin Oncol 23:9022-8. 2005
    ..We present a review of the various vaccine-based strategies employed to target and treat NSCLC...
  50. doi request reprint Metastatic pancreatic adenocarcinoma: current standards, future directions
    Austin Duffy
    Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
    Am J Ther 17:79-85. 2010
    ..This review attempts to summarize the standard therapeutic approach to metastatic pancreatic cancer and point to areas that hold promise for the future...
  51. doi request reprint Treatment of recurrent metastatic colon cancer in the age of modern adjuvant therapy
    Carla Kurkjian
    Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD 20892, USA
    Clin Colorectal Cancer 7:321-4. 2008
    ..Herein, we present approaches to the chemotherapeutic management of such patients with a review of the literature...
  52. ncbi request reprint Establishing a platform for immunotherapy: clinical outcome and study of immune reconstitution after high-dose chemotherapy with progenitor cell support in breast cancer patients
    Claude Sportes
    Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, 10 Center Dr, CRC Room 43142, Bethesda, MD 20892 1203, USA
    Biol Blood Marrow Transplant 11:472-83. 2005
    ..The described observations provide the basis for devising a strategy for cancer vaccine administration after ASCT. Incorporating immune reconstitution enhancement after ASCT may be advantageous...